title: An application of the Zucker-Wittes modified ratio estimate statistic in the Post Coronary Artery Bypass Graft (CABG) clinical trial.
abstract: In the Post Coronary Artery Bypass Graft (POST CABG) clinical trial, the primary outcome is substantial worsening (i.e., narrowing of the lumen diameter) of the vein grafts upon comparison of the baseline and follow-up angiograms. The patients had one to five non-occluded vein grafts at entry, so there may be from one to five primary outcome responses per patient. A modified ratio estimate (MRE) statistic, as described previously by Zucker and Wittes, may be used to analyze data of this kind. In the present paper we propose a more powerful MRE statistic when the event rates and/ or intraclass correlations vary according to number of grafts per patient. We also adapt this statistic to the factorial treatment design of the POST CABG clinical trial.
authors.affiliation: Maryland Medical Research Institute, Baltimore 21210, USA.
authors.forename: P L
authors.initials: PL
authors.lastname: Canner
authors.forename: B
authors.initials: B
authors.lastname: Thompson
authors.forename: G L
authors.initials: GL
authors.lastname: Knatterud
authors.forename: N
authors.initials: N
authors.lastname: Geller
authors.forename: L
authors.initials: L
authors.lastname: Campeau
authors.forename: D
authors.initials: D
authors.lastname: Zucker
mesh_terms: D000924:Anticholesteremic Agents / Q000008:administration & dosage / Q000009:adverse effects; D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects; D003131:Combined Modality Therapy; D017023:Coronary Angiography; D001026:Coronary Artery Bypass / Q000706:statistics & numerical data*; D003327:Coronary Disease / Q000401:mortality / Q000601:surgery*; D003627:Data Interpretation, Statistical; D004311:Double-Blind Method; D005500:Follow-Up Studies; D006801:Humans; D008148:Lovastatin / Q000008:administration & dosage / Q000009:adverse effects; D012501:Saphenous Vein / Q000637:transplantation; D014859:Warfarin / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D000924:Anticholesteremic Agents; D000925:Anticoagulants; D014859:Warfarin; D008148:Lovastatin